Has Lubna Mirza, MD received payments from drug or device companies?

Yes. Drug and device makers reported $836,565 in general payments to Lubna Mirza, MD across 1,772 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lubna Mirza, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lubna Mirza, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lubna Mirza, MD

Endocrinology, Diabetes & Metabolism · Norman, OKNPI 1326208513

Payments from drug & device makers

$836,565in general payments, 2019–2025

Across 1,772 payments — averaging $472.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk AS$543K
Kowa Research Institute, Inc.$157K
AbbVie$77K
Sanofi US Services Inc.$37K
AstraZeneca$10K
Astrazeneca UK Limited$4K
plus $9K from 48 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk AS	1,217	$542,641
Kowa Research Institute, Inc.	34	$157,427
AbbVie	33	$77,290
Sanofi US Services Inc.	48	$36,600
AstraZeneca(2 entities)	35	$10,025
Astrazeneca UK Limited	6	$3,934
Tandem Diabetes Care, Inc.	14	$1,217
Novo Nordisk	59	$973
Lilly USA, LLC	54	$808
Amgen(2 entities)	32	$729
Sanofi-aventis U.S. LLC	24	$537
Xeris Pharmaceuticals, Inc.	26	$469
Corcept Therapeutics	14	$382
Johnson & Johnson	19	$331
Insulet Corporation	15	$292
Abbott	12	$226
Madrigal Pharmaceuticals	6	$161
Recordati_rare_diseases_inc.	5	$153
Medtronic(2 entities)	7	$138
Boehringer Ingelheim	7	$133
Bayer	8	$129
Dexcom, Inc.	6	$126
Esperion Therapeutics, Inc.	1	$125
Merck	8	$125
IBSA Pharma Inc.	8	$121
BETA Bionics, Inc.	7	$118
Antares Pharma, Inc.	7	$118
Mannkind Corporation	5	$111
Ascendis Pharma Endocrinology Inc	5	$103
Radius Health, Inc.	3	$95
Chiesi USA, Inc.	5	$92
Cequr Corporation	3	$87
Ultragenyx Pharmaceutical Inc.	4	$84
Neurocrine Biosciences, Inc.	3	$77
Amarin Pharma, Inc.	4	$68
Lifescan, Inc.	3	$50
Ipsen Biopharmaceuticals, Inc	2	$48
Baxter Healthcare	2	$45
Amneal Pharmaceuticals LLC	2	$43
Echosens North America, Inc.	2	$41
Currax Pharmaceuticals LLC	3	$39
Ascensia Diabetes Care US Inc.	2	$34
Nevro Corp.	1	$24
Amryt Pharma Holdings Ltd	1	$23
Novartis	1	$22
Sequel Med Tech, LLC	1	$21
Rhythm Pharmaceuticals, Inc.	1	$21
GSK	1	$21
Eisai Inc.	1	$20
Gilead	1	$19
Boston Scientific	1	$16
BD	1	$13
Shire North American Group Inc	1	$13
Valeritas, Inc.	1	$12

How this compares

$836,565 in reported general payments places this provider in the 95th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.

See all endocrinology, diabetes & metabolism providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$407,513

Medicare patients

431

Services billed

24,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Norman

Tan PhamNorman$7K
Shelley McClureNorman$3K
Cassie SmithEdmond$629K
Matthew DraelosEdmond$392K
Robert ScofieldOklahoma City$189K
Jonea LimOklahoma City$172K
Cristin BrunsTulsa$159K
Donald AspensonTulsa$153K
Christian MangrumOklahoma City$54K
Elie AbedTulsa$27K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →